SCA
HAE icon

SAC Capital Advisors’s Haemonetics HAE Stock Holding History

SAC Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-43,161
Closed -$1.41M – 434
2014
Q1 		$1.41M Buy
43,161
+24,155
+127% +$923K 0.01% 854
2013
Q4 		$801K Buy
+19,006
New +$782K ﹤0.01% 992
2013
Q3 		– Sell
-14,644
Closed -$606K – 1843
2013
Q2 		$606K Buy
+14,644
New +$593K ﹤0.01% 1041

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

SAC Capital Advisors's HAE Position: Q2 2014 in Review

SAC Capital Advisors sold out of Haemonetics (HAE) in Q2 2014, closing a stake of 43,161 shares — an estimated $1.41M sold.

SAC Capital Advisors first reported a position in HAE in Q2 2013 and held it in 3 quarters. The position peaked at $1.41M in Q1 2014. 175 funds tracked by Wall St. Rank hold HAE as of Q2 2014.

  • SAC Capital Advisors reported no remaining Haemonetics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 43,161 Haemonetics shares in Q2 2014, an estimated $1.41M.
  • SAC Capital Advisors first reported a position in Haemonetics in Q2 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Haemonetics position peaked at $1.41M in Q1 2014.
  • 175 funds tracked by Wall St. Rank held Haemonetics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.